Ablavar (previously Vasovist) (gadofosveset trisodium)
- Region
- 🇪🇺 EU
- Active substance
- gadofosveset trisodium
- Company
- TMC Pharma Services Ltd.
- Status
- Withdrawn
- Therapeutic area
- Magnetic Resonance Angiography
- EU approval
- Mon 03 Oct 2005
- Application
- EMEA/H/C/000601
- ATC
- V08CA
- Official record
- www.ema.europa.eu
Indication
This medicinal product is for diagnostic use only. Ablavar is indicated for contrast-enhanced magnetic resonance angiography (CE-MRA) for visualisation of abdominal or limb vessels in adults only, with suspected or known vascular disease.
Regulatory milestones
No milestones recorded in the last year.
Follow Ablavar (previously Vasovist)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.